Yesterday, the migraine community was abuzz with the news that the FDA finally approved the first drug in a line of new migraine preventatives, a CGRP blocker named Aimovig. As the story was the number one trending story on the New York Times website for most of today, I’m not going to go into details about Aimovig or CGRPs in general. However, if you’re looking for more information on the treatment, the science behind it, or what else is still to come, I’ve compiled a list of links that may help. And, if you want to get a glimpse of how amazingly important this development is to the migraine community at large, take a look at my friend Katie’s video tweet from yesterday. I think many of us can relate to her joy. I know I certainly can.
What to Expect: Patient Experiences with CGRP
Noteworthy Responses to CGRP Approval
Long-time advocate Kerrie Smyres wrote a response to the impending FDA approval just a few days before the official announcement. In addition to being a personal friend, Kerrie is also one of my favorite migraine writers. And, in this piece, she shares some of her fears about the CGRP drugs — fears she and I have discussed in detail because I share them, too. While I’m definitely excited about this development in preventative therapy, I feel it’s important to consider the flip side of any new treatment. Particularly when it’s one so many people are relying on so heavily.
And, to balance those worries, I’m also sharing a poem written by another one of my fellow Migraine.com advocates who has a personal history with the CGRP therapies. She’s ecstatic and was even months before the approval.